Astrazeneca earnings were $10.4B for the trailing 12 months ending Jun 30, 2026, with 26% growth year over year. The latest AZN earnings report on Jun 30, 2026 announced Q2 2026 earnings of $2.5B, down 18.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AZN reported annual earnings of $10.2B, with 45.3% growth.
AZN past earnings growth
How has AZN's earnings growth performed historically?
On AZN's earnings call on Jul 27, 2026, Astrazeneca (NYSE: AZN) reported Q2 2026 earnings per share (EPS) of $1.61, up 1.9% year over year. Total AZN earnings for the quarter were $2.51 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $1.58.
As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $10.45 billion, a 25.93% increase year over year.
What was AZN's earnings growth in the past year?
As of Astrazeneca's earnings date in Jul 27, 2026, Astrazeneca's earnings has grown 25.98% year over year. This is 10.19 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 36.17%. AZN earnings in the past year totalled $10.45 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.